|
|
|
| home > white papers > Biosimilars In Emerging Markets: Is It A Level Playing Field? - PRA Health Sciences (PRA) |
|
|
 WHITE PAPERS |
|
PRA Health Sciences (PRA)
|
|
Biosimilars In Emerging Markets: Is It A Level Playing Field?
|
|
Governments, healthcare payers, and social and health reforms, combined
with the increased incidence of conditions such as cancer and diabetes
are paving the way for increased uptake of biologic medicines in
emerging markets. However, expensive biologic medicines can be
prohibitive to many patients, creating a high level of unmet clinical
need. At its best, the global expansion of biosimilars can mean a robust
and steady supply of existing and new drugs reaching far-flung patient
populations, but localized biosimilar drug developments, especially in
China and India, combined with a lack of robust pharmacovigilance
systems, threaten to derail the industry by putting patient health at
risk.
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
RWS Life Sciences Welcomes New VP of Quality
RWS Life Sciences welcomes Clarice Streets, ASQ, CMQ, OE, as Vice
President, Global Quality and Process, in charge of the strategic
direction and implementation of its Quality system, underlying
organizational processes, and change management.
More info >> |
|
 |
White Papers |
 |
|
Orthogonal Approaches for the Analysis of Protein Sequence and Post Translational Modifications of a Monoclonal Antibody
RSSL
Monoclonal antibodies are an important class of biopharmaceuticals. They are expressed from living cells and therefore, are subject to complex biochemical pathways. Not all of these pathways are fully understood and many are known to be sensitive to subtle environmental changes during production. These changes may affect the final biopharmaceutical sequence, structure and post-translational modifications. This is in addition to any changes that may occur during subsequent purification. This means that the final product from one batch may be subtly different from another batch. Furthermore, each batch is a heterogeneous mix of similar molecules. Analysis of the degree of batch-tobatch variation, and batch heterogeneity, is therefore, very important to establish in order to be confident that the drug is safe and effective for medicinal use.
More info >> |
|
 |
Industry Events |
 |
BioPharm America 2018
5-6 September 2018, Hynes Convention Center
BioPharm America™ is a unique partnering event that forms the nexus of discovery and realization. Startup companies, established biotech and entrepreneurs from academia attend in search of finance, pharma and development partners. The event format highlights innovation and promotes new business relationships by bringing dealmakers from the life science ecosystem together to engage and de-risk the enormous task of drug development.
More info >> |
|
|
|
